Literature DB >> 2893992

Nerve fibers surrounding intracranial and extracranial vessels from human and other species contain dynorphin-like immunoreactivity.

M A Moskowitz1, K Saito, L Brezina, J Dickson.   

Abstract

Dynorphin B(20-32) was visualized by immunohistochemistry in guinea-pig and rat perivascular nerve fibers and was measured by radioimmunoassay within the walls of feline, canine, bovine and human cephalic and systemic arteries and veins. Canine vessels contained the highest levels. When human blood vessels or trigeminal ganglia were subjected to reverse-phase high-performance liquid chromatography, dynorphin immunoreactivity exhibited a retention time identical to that of synthetic dynorphin B. No differences in dynorphin-like immunoreactivity were measurable between feline systemic arteries and veins, or between cephalic and systemic vessels. The highest amounts were present in leptomeninges devoid of large pial arteries. Relatively high levels were also measured in feline and human trigeminal ganglia and feline superior cervical and sphenopalatine ganglia, three sources of projecting perivascular axons. Levels did not diminish, however, in ipsilateral feline cephalic vessels following either unilateral trigeminal or superior cervical ganglionectomies. Hence, dynorphin-containing fibers may project from parasympathetic cell bodies or perhaps from intrinsic brain sources. Previously published reports indicate that the kappa agonist dynorphin does not modify vessel tone when added in vitro but does inhibit release of neurotransmitters from afferent and sympathetic axons via prejunctional receptors. These observations suggest a pharmacological role for dynorphin on sensory and autonomic functions of the vasculature.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2893992     DOI: 10.1016/0306-4522(87)90090-x

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  3 in total

Review 1.  Dynorphins in Development and Disease: Implications for Cardiovascular Disease.

Authors:  Cody Cissom; Jason J Paris; Zia Shariat-Madar
Journal:  Curr Mol Med       Date:  2020       Impact factor: 2.222

2.  Close apposition of dynorphin-positive nerve fibres to lymphocytes in the liver suggests opioidergic neuroimmunomodulation.

Authors:  Matthias J T Kaiser; Gisa Tiegs; Winfried L Neuhuber
Journal:  Histochem Cell Biol       Date:  2003-08-05       Impact factor: 4.304

3.  Perivascular expression and potent vasoconstrictor effect of dynorphin A in cerebral arteries.

Authors:  Éva Ruisanchez; Attila Cselenyák; Rege Sugárka Papp; Tamás Németh; Krisztina Káldi; Péter Sándor; Zoltán Benyó
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.